REAL-WORLD COSTS AND HEALTHCARE RESOURCE UTILIZATION (HRU) PATTERNS IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (R/R-MCL) PATIENTS POST-IBRUTINIB FAILURE

被引：0
|
作者：
Lam, J. [1 ]
Lin, V. W. [2 ]
Purdum, A. G. [2 ]
机构：
[1] Univ Southern Calif, Los Angeles, CA USA
[2] Kite, Santa Monica, CA USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.227
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN103
引用
收藏
页码：S75 / S75
页数：1
相关论文
共 50 条
  • [41] Real-world treatment patterns, healthcare resource utilization (HRU), and costs of initial line of therapy (LOT1) in multiple myeloma (MM)
    Byfield, Stacey DaCosta
    Bancroft, Tim
    Ma, Esprit
    Bonthapally, Vijayveer
    Teitelbaum, April H.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [42] Real world treatment patterns, healthcare resource utilization (HRU), and costs among Waldenstrom macroglobulinemia (WM) patients initiating therapy.
    Ellis, Lorie
    Byfield, Stacey DaCosta
    Korrer, Stephanie
    Schenkel, Brad
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [43] Real-world healthcare costs and resource utilization (HRU) among patients treated with erenumab in the United States: A retrospective claims database study
    Tepper, S. J.
    Schwedt, T. J.
    Vo, P.
    Joshi, P.
    Glassberg, M.
    Abdrabboh, A.
    Ferraris, M.
    Tiwari, S.
    Thompson, J.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 26 - 26
  • [44] Treatment Utilization Patterns, Health Resource Use, Costs, and Survival in Mantle Cell Lymphoma: A Real-World Analysis of a National Sample of Medicare Beneficiaries
    Squires, Patrick
    Huntington, Scott F.
    Puckett, Justin
    Ryland, Katherine Elizabeth
    Kamal-Bahl, Sachin
    Raut, Monika
    Doshi, Jalpa
    BLOOD, 2022, 140 : 5041 - 5042
  • [45] Real-World Outcomes in Patients With Relapsed or Refractory (r/r) Aggressive Large B-Cell Lymphoma (LBCL) Treated With Chemo-Immunotherapy
    Nastoupil, Loretta J.
    Andersen, Clark
    Ayers, Amy
    Wang, Yucai
    Habermann, Thomas M.
    Chihara, Dai
    Kahl, Brad S.
    Link, Brian K.
    Ayyappan, Sabarish
    Cohen, Jonathon B.
    Martin, Peter
    Lossos, Izidore S.
    Casulo, Carla
    Lin, Ruitao
    Li, Ziyi
    Larson, Melissa A.
    Maurer, Matthew J.
    Huynh, Lynn
    Gao, Chi
    Ramasubramanian, Ramya
    Duh, Mei Sheng
    Mutebi, Alex
    Wang, Tongsheng
    Jun, Monika
    Wang, Anthony
    Kamalakar, Rajesh
    Kalsekar, Anupama
    Cerhan, James R.
    Flowers, Christopher R.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S442 - S443
  • [46] Real-world healthcare resource utilization (HRU)/costs associated with venetoclax treatment among chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) patients.
    Rogers, Kerry Anne
    Emond, Bruno
    Manceur, Ameur M.
    Kinkead, Frederic
    Lafeuille, Marie-Helene
    Lefebvre, Patrick
    Huang, Qing
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [47] REAL-WORLD TREATMENT PATTERNS AND COSTS IN RELAPSED AND REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN THE UNITED STATES
    Mutebi, A.
    Jun, M.
    Flores, C.
    Wang, Z.
    Wang, A.
    Elliot, B.
    Navarro, F. R.
    Kalsekar, A.
    VALUE IN HEALTH, 2022, 25 (07) : S394 - S394
  • [48] Real-world adherence and healthcare resource utilization of Bruton tyrosine kinase inhibitors (BTKi) in mantle cell lymphoma.
    Shah, Bijal D.
    Furnback, Wesley
    Esselman, Kaitlyn
    Chuang, Po-Ya
    Xue, Mei
    Yang, Keri
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [49] Tafasitamab for the Treatment of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in the US Real-World Setting
    Saverno, Kimberly
    Savill, Kristin M. Zimmerman
    Feinberg, Bruce
    Galvin, John
    Pathak, Prathamesh
    Gordon, Sarah
    Amoloja, Theresa
    Llorente, Mae
    Epperla, Narendranath
    Nastoupil, Loretta J.
    BLOOD, 2023, 142
  • [50] Real-world treatment patterns, health care resource utilization (HRU), and costs among patients with Waldenstrom macroglobulinemia (WM) initiating therapy
    Schenkel, Brad
    Ellis, Lorie
    Korrer, Stephanie
    Byfield, Stacey DaCosta
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (07)
12345